The PPARγ Agonist Rosiglitazone Suppresses Syngeneic Mouse SCC (Squamous Cell Carcinoma) Tumor Growth through an Immune-Mediated Mechanism

Recent evidence suggests that PPARγ agonists may promote anti-tumor immunity. We show that immunogenic PDV cutaneous squamous cell carcinoma (CSCC) tumors are rejected when injected intradermally at a low cell number (1 × 10(6)) into immune competent syngeneic hosts, but not immune deficient mice. A...

Descripción completa

Detalles Bibliográficos
Autores principales: Konger, Raymond L., Derr-Yellin, Ethel, Ermatov, Nurmukambed, Ren, Lu, Sahu, Ravi P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6600265/
https://www.ncbi.nlm.nih.gov/pubmed/31212694
http://dx.doi.org/10.3390/molecules24112192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6600265/
https://www.ncbi.nlm.nih.gov/pubmed/31212694
http://dx.doi.org/10.3390/molecules24112192

Ejemplares similares